In fact, from Merck's $1.3 billion deal to GSK's $850 million investment, the "gold content" of Chinese companies' self-developed TCE bispecific antibodies has already been well proven. The new moves ...
As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, ZUNVEYL demonstrates a potentially better safety ...